Micheletti J Morgan, Shultz Mitchell, Singh Inder Paul, Samuelson Thomas W
Berkeley Eye Center, 1435 Hwy 6, Suite #202, Sugar Land, TX, 77478, USA.
Shultz Chang Vision, Northridge, CA, USA.
Ophthalmol Ther. 2025 Jan;14(1):13-22. doi: 10.1007/s40123-024-01073-z. Epub 2024 Nov 30.
The glaucoma treatment paradigm is in evolution. The topical medications-first approach is limited by significant barriers such as high rates of nonadherence and side effects including ocular surface disease. The era of interventional glaucoma has seen the development of selective laser trabeculoplasty (SLT), procedural pharmaceuticals, and minimally invasive glaucoma surgeries (MIGS). New and emerging data support the use of these interventional treatment modalities early in the course of glaucoma rather than reserving them for advanced or treatment-recalcitrant cases. The various treatments available represent multiple mechanisms (e.g., trabecular outflow, uveoscleral outflow, aqueous suppression) and modalities (medications, laser, incisional surgery) by which intraocular pressure (IOP) is reduced. Many patients require more than one treatment to achieve adequate IOP reduction and glaucoma control. Comprehensive IOP control-reduction of both mean IOP and IOP fluctuation-can best be achieved by targeting multiple mechanisms of IOP reduction and taking advantage of the attributes of multiple treatment modalities.
青光眼的治疗模式正在不断演变。首先使用局部药物的方法受到诸多重大障碍的限制,如不依从率高以及包括眼表疾病在内的副作用。在青光眼介入治疗时代,出现了选择性激光小梁成形术(SLT)、手术用药物和微创青光眼手术(MIGS)。新出现的数据支持在青光眼病程早期使用这些介入治疗方式,而不是将它们留到晚期或治疗抵抗性病例中使用。现有的各种治疗方法代表了多种降低眼压(IOP)的机制(如小梁网流出、葡萄膜巩膜流出、房水抑制)和方式(药物、激光、切开手术)。许多患者需要不止一种治疗才能充分降低眼压并控制青光眼。通过针对多种降低眼压的机制并利用多种治疗方式的特性,能够最好地实现全面的眼压控制,即降低平均眼压和眼压波动。